Strategy & Approach

Mr. Bikoff is a Managing Director at Longitude Capital. Prior to joining Longitude Capital in 2016, Mr. Bikoff held a series of strategy, finance, and operating roles at Cardinal Health. While at Cardinal Health, he worked to deploy over $6 billion of capital through M&A and minority investments. Most recently, Mr. Bikoff was the Director of North America Marketing for the Cordis cardiovascular franchise. Mr. Bikoff currently serves on the boards of Kestra Medical and Polares Medical, and is a board observer at Bolt Medical. He previously served as a board observer at Amphora (acquired), Ceribell (CBLL), Eargo (EAR), Endogenex, LimFlow (acquired by Inari Medical), Nalu Medical, and RxSight (RXST), and was also actively involved in Longitude Capital’s investment in Axonics Modulation Technologies (AXNX) and PROCEPT BioRobotics (PRCT). Mr. Bikoff began his career in Deloitte Consulting’s Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University.
—
Focus Areas: Medical Technology
Location: Menlo Park

Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund and he began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Hoffman – La Roche, and Novartis. Mr. Enright currently serves on the boards of BioAge Labs (BIOA), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Opna Bio, Orbus Therapeutics, Vera Therapeutics (VERA), Veradermics, and Zenas BioPharma (ZBIO). Selected prior board memberships include Aimmune (AIMT, acquired by Nestlé), Codexis (CDXS), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP, acquired by Amgen), InfaCare Pharmaceutical (acquired by Mallinckrodt), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sequenom (SQNM, acquired by LabCorp), Rivus Pharmaceuticals, Threshold Pharmaceuticals (THLD), Vaxcyte (PCVX), as well as the National Venture Capital Association (NVCA). Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.
—
Focus Areas: Biotechnology, Health Solutions
Location: Menlo Park

Mr. Galletti is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Galletti was a Senior Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Mr. Galletti worked at Amerindo Investment Advisors, Vector Fund Management, and the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his career in the life sciences industry at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals. Mr. Galletti currently serves on the board of Murj. Selected prior board memberships include Amphora Medical (acquired), Aptus Endosystems (acquired by Medtronic), and Twelve (acquired by Medtronic), and he has also been involved with prior investments in Ablation Frontiers (acquired by Medtronic), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sadra Medical (acquired by Boston Scientific), and Threshold Pharmaceuticals (THLD). Mr. Galletti previously served on advisory boards for the Innovation and New Ventures Office at Northwestern University and the Life Sciences Advisory Board of Silicon Valley Bank. Mr. Galletti holds an MBA in Finance and Health Services Management from the Kellogg School of Management at Northwestern University and an AB from Princeton University.
—
Focus Areas: Medical Technology, Health Solutions
Location: Menlo Park

Ms. Helms is a Managing Director and the Chief Financial Officer at Longitude Capital. Ms. Helms is responsible for the financial reporting of the Firm’s investment funds, as well as the day-to-day management of Firm-wide finance, tax, human resources, IT, and administration. In addition, Ms. Helms supports the Firm’s regulatory compliance program and works closely on legal, investor relations, and other operational matters. Ms. Helms served as the Firm’s Chief Compliance Officer from 2014 to September 2021. Prior to joining Longitude Capital in 2008, Ms. Helms was the Controller at Sierra Ventures, a venture capital firm focused on technology. Prior to Sierra Ventures, Ms. Helms was an Accounting Manager at NetManage, a publicly-traded software company, and was a Senior Auditor with Arthur Andersen LLP. Ms. Helms is a licensed CPA (inactive) and graduated cum laude with a BS in Business Administration (Accounting) from San Jose State University.
—
Focus Areas: Finance, Operations, Compliance
Location: Menlo Park

Dr. Liu is a Managing Director at Longitude Capital. Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals and medical products practice of McKinsey & Company. Dr. Liu currently serves on the boards of Alentis Therapeutics, CG Oncology (CGON), Helicore Biopharma, and Lassen Therapeutics. Dr. Liu also currently serves as a board observer at Quanta Therapeutics. He previously served as a board observer at Dascena, Endeavor Biomedicines, Inflazome (acquired by Roche), Rivus Pharmaceuticals, Tourmaline Bio (TRML; formerly known as Talaris Therapeutics (TALS)), Vera Therapeutics (VERA), and Zenas Biopharma (ZBIO) and was also actively involved in Longitude Capital’s investment in Strongbridge Biopharma (SBBP; acquired by Xeris Biopharma). Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University.
—
Focus Areas: Biotechnology
Location: Menlo Park

Mr. Wert is a Managing Director at Longitude Capital. Mr. Wert was previously with Longitude Capital from 2008 to 2012 and rejoined in 2016. Before that, he was a Vice President at Warburg Pincus, where he focused on healthcare investments. Prior to joining Longitude Capital, Mr. Wert worked in the Global Healthcare Investment Banking Group at Merrill Lynch. Mr. Wert currently serves on the board of Cortica, On Belay Health, and WelbeHealth, and is a board observer at Cohere Health and Murj. He previously served as a board observer at California Cryobank (acquired by GI Partners and now known as Generate Life Sciences) and Somatus, and was also actively involved in Longitude Capital’s investments in IntelyCare and NOCD. While at Warburg Pincus, Mr. Wert served as a board observer at Silk Road Medical (SILK), Outset Medical (OM), and Accriva Diagnostics (acquired by Werfen). Mr. Wert holds an MBA from Stanford Graduate School of Business, where he was an Arbuckle Leadership Fellow and received a Certificate in Social Innovation and Public Management. He received his dual-degree BA in Biochemistry, Biophysics, and Molecular Biology (BBMB), and Economics with honors from Whitman College, graduating magna cum laude and Phi Beta Kappa.
—
Focus Areas: Health Solutions
Location: Menlo Park

Mr. Young is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to Jazz, Mr. Young was an investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman Brothers, and Merrill Lynch, where he advised and led financings for hundreds of emerging and established life science companies. Additionally, Mr. Young served on the board of PRA Health Sciences (PRAH) until its acquisition by ICON plc for $12 billion in 2021, and currently serves as Lead Independent Director and Chairman of the Audit Committee of CytomX Therapeutics (CTMX). Mr. Young also serves as a board member of Alpha-9 Therapeutics and OrsoBio, and was actively involved in Longitude Capital’s investment in Mirum Pharmaceuticals (MIRM). Mr. Young holds an MBA and a BS in Economics from the Wharton School of the University of Pennsylvania.
—
Focus Areas: Biotechnology
Location: Menlo Park

Mr. Kim is a Senior Associate at Longitude Capital. Prior to joining Longitude Capital in 2024, Mr. Kim was a Senior Manager at Transcarent, where he held various roles on the Finance team to help scale the company’s breadth of offerings. He also held various operating roles at Truepill, where he helped start its consumer diagnostics business. Prior to that, Mr. Kim was a Healthcare Investment Associate at GI Partners and an Investment Banking Analyst at Evercore Partners. Mr. Kim holds a BA in Philosophy, Political Science, and Economics from the University of Pennsylvania.
—
Focus Areas: Health Solutions
Location: Menlo Park

Ms. Chen is an Associate at Longitude Capital. Prior to joining Longitude Capital in 2024, Ms. Chen was an Investment Banking Analyst at Morgan Stanley in the Healthcare group, where she focused on the biopharmaceutical sector. Ms. Chen holds a MS in Biology and a BS in Human Biology with a minor in Management Science and Engineering from Stanford University.
—
Focus Areas: Biotechnology
Location: Boston

Dr. Ely is a Senior Associate at Longitude Capital. Prior to joining Longitude Capital full-time in 2022, Dr. Ely was a Longitude Research Fellow. Dr. Ely’s work has been published in several leading journals, including Nature Biotechnology, Cancer Cell, and Nature Cancer. Dr. Ely serves as a board observer at Alpha-9 Theranostics, Helicore Bioventures, and Opna Bio. Dr. Ely earned a PhD in Biology from the Massachusetts Institute of Technology, where he specialized in gene editing and cancer immunology, and a BA in Molecular and Cellular Biology from Vanderbilt University.
—
Focus Areas: Biotechnology
Location: Boston

Mr. Gupta is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2020, Mr. Gupta was a Consultant in the MedTech practice at L.E.K. Consulting, where he focused on growth strategy and M&A for corporate and private equity clients in the medical device industry. Mr. Gupta currently serves as a board observer at Endogenex and Nalu Medical, and was actively involved in Longitude Capital’s investments in Ceribell (CBLL), Eargo (EAR), LimFlow, PROCEPT BioRobotics (PRCT), and an undisclosed medical technology company. He holds a BS and MS in Biomedical Engineering from the Robert R. McCormick School of Engineering and Applied Science at Northwestern University.
—
Focus Areas: Medical Technology
Location: Menlo Park

Ms. Jamison is a Manager of Investor Relations and Marketing at Longitude Capital. Prior to joining Longitude Capital in 2019, Ms. Jamison was an Account Manager at BBDO serving the Allergan and Bayer Crop Science accounts, where she led the development and launch of multi-channel marketing campaigns. Ms. Jamison holds a BA in Marketing and International Business from the University of Georgia.
—
Focus Areas: Investor Relations & Marketing
Location: Menlo Park

Ms. Lai is a Vice President at Longitude Capital. Prior to joining Longitude Capital in 2021, Ms. Lai was an Investor at HealthQuest Capital, a healthcare venture growth investment firm, where she executed investments across growth-stage healthcare companies including Everly Health, Thirty Madison, and ENT Specialty Partners. Prior to HealthQuest Capital, Ms. Lai was a Director at CarePoint Health System, where she held roles in strategy and operations and helped to build and run value-based care organizations. She also worked in the Healthcare Investment Banking Group at Goldman Sachs. Ms. Lai is a board observer at Cortica, NOCD, On Belay Health Solutions, and WelbeHealth. She was also actively involved in Longitude Capital’s investment in IntelyCare. Ms. Lai holds an MBA from Columbia Business School and a BA in Human Biology from Stanford University.
—
Focus Areas: Health Solutions
Location: Menlo Park

Dr. Lim is a Senior Analyst focusing on public equities at Longitude Capital. Prior to joining Longitude Capital in 2024, Dr. Lim was an Analyst at Deep Track Capital, Lynx1, and Walleye Capital, where he focused on biotechnology long/short public equities. Prior to that, Dr. Lim was an Investment Banking Vice President at Jefferies, where he covered healthcare companies. Dr. Lim holds a PhD in Neurobiology from California Institute of Technology, and an MS in Cancer Immunology and a BS in Molecular Biology from the University of California, San Diego.
—
Focus Areas: Biotechnology
Location: Boston

Dr. Vanhove is a Venture Partner at Longitude Capital. Dr. Vanhove has more than 25 years of clinical drug development and medical affairs experience across small and large biopharmaceutical companies. Prior to joining Longitude Capital in 2023, Dr. Vanhove most recently served as Chief Medical Officer of Surrozen (SRZN), a biotechnology company focused on discovering and developing novel regenerative medicines. Prior to Surrozen, Dr. Vanhove served as Vice President, Medical Affairs and, subsequently, Vice President of Search and Evaluation at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company. Prior to Jazz Pharmaceuticals, she served as Vice President, Medical Affairs at Depomed, Vice President, Clinical Development at NeurogesX, and a Medical Director at XOMA. She began her career as a Medical Director at Abbott Laboratories. Dr. Vanhove holds an MD and a PhD in Pharmacology from the Catholic University in Leuven, Belgium. She completed a fellowship in clinical pharmacology at Stanford University and holds an MBA from St. Mary’s College. Dr. Vanhove has authored, or co-authored, dozens of peer-reviewed articles, and is an inventor of numerous patents.
—
Focus Areas: Biotechnology
Location: Menlo Park

Dr. Wang is a Vice President at Longitude Capital. Prior to joining Longitude Capital in 2022, Dr. Wang was the Senior Director of Strategy & Corporate Development at Dascena, a Longitude portfolio company. Prior to Dascena, Dr. Wang was an Engagement Manager at L.E.K. Consulting, where she consulted life sciences companies on drug development, commercial, and portfolio strategy. Dr. Wang currently serves as a board observer at CuraSen Therapeutics, Endeavor Biomedicines, Lassen Therapeutics, and Orbus Therapeutics. She previously served as a board observer at Epirium Bio. She was actively involved in Longitude Capital’s investment in BioAge Labs. Dr. Wang holds a PhD in Chemical Biology from the University of California, Berkeley, and a BA in Chemical and Physical Biology from Harvard University.
—
Focus Areas: Biotechnology
Location: Menlo Park

Ms. Zehfuss is an Associate at Longitude Capital. Prior to joining Longitude Capital in 2022, Ms. Zehfuss assisted Draper Associates, an early-stage venture capital firm, in identifying potential investment opportunities through the University of Oxford start-up ecosystem. Ms. Zehfuss holds an MPhil from the University of Oxford and a BS in Human Biology from Stanford University.
—
Focus Areas: Health Solutions
Location: Menlo Park

Ms. Caruso Wilson is a Compliance and Legal Associate at Longitude Capital. Prior to joining Longitude Capital in 2022, Ms. Caruso Wilson was a Compliance Consultant at ACA Global (formerly known as ACA Compliance), where she advised SEC-registered investment advisers on U.S. federal securities laws and helped develop and administer regulatory compliance programs for her clients. Ms. Caruso Wilson received her JD from the University of San Francisco School of Law and holds a BA in Political Science with a double minor in Criminology and Italian Language and Culture Studies from Marquette University.
—
Focus Areas: Legal, Compliance
Location: Menlo Park

Ms. Rood is an Executive Assistant at Longitude Capital supporting the Medical Technology and Investment Relations teams as well as the CFO. Prior to joining Longitude in 2019, Ms. Rood was an Executive Assistant at Egon Zehender supporting Consultants. Previously, Ms. Rood was an Executive Assistant at Omidyar Network. Ms. Rood holds a BA in Communications from San Jose State University.
—
Location: Menlo Park

Ms. Helene is an Executive Assistant at Longitude Capital, supporting the Health Solutions, Medical Technology, and Finance teams. Prior to joining Longitude Capital in 2023, Ms. Helene was an Executive Assistant at Freshfields Bruckhaus Deringer. Previously, Ms. Helene was an Executive Assistant at Vedder Price. Ms. Helene holds a MSt in International Relations from the University of Cambridge and a BA in History from the University of California, San Diego.
—
Location: Menlo Park

Ms. Holman is a Controller at Longitude Capital. Prior to joining Longitude Capital in 2013, Ms. Holman was an Audit Associate with Moss Adams LLP and PricewaterhouseCoopers LLP, where she served technology and life sciences companies, as well as venture capital firms. Ms. Holman holds a BS in Microbiology from San Jose State University and a Certificate of Advanced Accounting Proficiency from Santa Clara University.
—
Location: Menlo Park

Ms. Hughes is an Executive Assistant at Longitude Capital supporting both the Biotechnology and Medical Technology teams. Prior to joining Longitude Capital in 2007, Ms. Hughes was an Executive Assistant at Pequot Ventures. Previously, Ms. Hughes served as an Executive Assistant at Pollock Financial Group. Ms. Hughes holds a BA in Sociology from Menlo College.
—
Location: Menlo Park

Mr. Jonson is the Director of IT at Longitude Capital. Prior to joining Longitude Capital in 2023, Mr. Jonson worked for AllCovered, where he held roles as Senior Systems Engineer, Engineering Team Lead, and Senior Professional Services Engineer. Mr. Jonson has over 15 years of work experience at Managed IT Service Providers and several venture capital firms, where he managed and oversaw IT operations. Mr. Jonson holds a BS in Network Communications Management from DeVry University, Fremont.
—
Focus Areas: IT
Location: Menlo Park

Ms. Lok is a Vice President of Finance at Longitude Capital. Prior to joining Longitude Capital in 2015, Ms. Lok spent seven years at KPMG LLP (formerly Rothstein Kass) in audit and assurance, with a focus on life science venture capital funds. Ms. Lok holds a BA in Economics with an emphasis in Accounting from the University of California, Santa Barbara.
—
Location: Menlo Park

Ms. Mercado is a Staff Accountant at Longitude Capital. Ms. Mercado was previously with Longitude Capital from 2011 to 2016 and rejoined in 2019. Prior to initially joining Longitude in 2011, Ms. Mercado was a Senior Tax Associate at Frank, Rimerman + Co. LLP, where she served the tax needs of small investment companies as well as venture capitalists. Ms. Mercado is a licensed CPA and holds a BS in Business Administration from California Polytechnic State University, San Luis Obispo with a Concentration in Public Accounting.
—
Location: Menlo Park

Ms. Moimoi is an Assistant to the Investor Relations & Marketing and Administration teams. Prior to joining Longitude Capital in 2017, Ms. Moimoi was a mentor and representative at the LEMO Foundation, a non-profit organization that works with at-risk youth. Ms. Moimoi holds a BA in Marketing from the University of Mississippi.
—
Location: Menlo Park

Ms. Oliveira is the Head of Legal as well as the Chief Compliance Officer at Longitude Capital. Prior to joining Longitude Capital in 2020, Ms. Oliveira was a Senior Associate at Weil, Gotshal & Manges LLP, where she counseled public and private companies, private equity firms, and venture funds in a wide range of matters, including mergers and acquisitions, securities law compliance, venture financings, and commercial arrangements. Ms. Oliveira graduated with highest honors from the University of California, Berkeley with a BA in Political Science and received a JD from the University of California, Berkeley, School of Law.
—
Focus Areas: Legal, Compliance
Location: Menlo Park

Ms. Shin is a Senior Tax Manager at Longitude Capital and a member of the Finance team. Prior to joining Longitude Capital in 2024, Ms. Shin was a Tax Manager at a16z. Prior to that, Ms. Shin held various tax-related roles at GI Partners, Pattern Energy Group, and PricewaterhouseCoopers LLP, with a focus on private equity and venture capital funds. Ms. Shin holds an MS in Taxation from Golden Gate University and a BA in Political Science from the University of California, Irvine.
—
Location: Menlo Park

Ms. Wright is an Executive Assistant at Longitude Capital. Prior to joining Longitude in 2018, Ms. Wright owned a Bar Method fitness studio. Previously, she worked in production at ABC News 20/20. Ms. Wright holds a BA in Communications from Fordham University.
—
Location: Boston